Correction of DiGeorge Anomaly with EBV-Induced Lymphoma by Transplantation of Organ-Cultured Thymus and Epstein–Barr-Specific Cytotoxic T Lymphocytes

Hong, Richard; Shen, Violet; Rooney, Cliona M.; Hughes, Dennis P.M.; Smith, Colton; Comoli, P.; Zhang, Linqi

doi:10.1006/clim.2000.4948

Cited by 20 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We could literally find only one case report of EBVassociated lymphoma with a "B-cell" phenotype [8]. It is said that T lymphocytes can acquire viral receptor CD21 on their membrane by conjugating EBV-infected B cells from the point of the immunologic synaptic transfer, although its amount was limited [9,10].…”

Section: Discussionmentioning

confidence: 99%

Epstein-Barr virus–positive T-cell lymphoma cells having chromosome 22q11.2 deletion: an autopsy report of DiGeorge syndrome

et al. 2011

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Epstein-Barr virus–positive T-cell lymphoma cells having chromosome 22q11.2 deletion: an autopsy report of DiGeorge syndrome

et al. 2011

View full text Add to dashboard Cite

“…[19][20][21] We have also been successful in generating autologous EBV-specific T cells from patients affected by Hodgkin disease or with congenital immunodeficiency, and in using these cells to control EBV-related diseases. 26,27 We have now investigated whether EBV-CTLs can regularly be generated from patients with mild/moderate forms of CAEBV and if infusion of these cells affects the symptoms, physical signs, and serologic markers of the disorder.…”

Section: Introductionmentioning

confidence: 99%

Autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for the treatment of persistent active EBV infection

Savoldo¹,

Huls

Liu

et al. 2002

Blood

136

View full text Add to dashboard Cite

Chronic active Epstein-Barr virus (CAEBV)infection syndrome is a heterogeneous EBV-related disorder characterized by chronic fatigue, fever, lymphadenopathy, and/or hepatosplenomegaly, associated with abnormal patterns of antibody to EBV. CAEBV can range from disabling mild/moderate forms to rapidly lethal disorders. Even patients with mild/moderate disease frequently suffer adverse effects from long-term anti-inflammatory agents and have a quality of life that progressively deteriorates. It is still unknown why these individuals are unable to produce an effective immune response to control EBV, and no effective treatment is currently available. Since ex vivo-expanded EBV-specific cytotoxic T lymphocytes

show abstract

“…In particular, EBV-specific CTL have been administered in a patient with DiGeorge syndrome, 52 a patient with primary central nervous system (CNS) B-cell lymphoma with recurrent infections, peculiar anti-EBV antibody pattern and reduced response to mitogens, 53 and a patient with AIDS-related lymphoma. 49 Once again, the CTL infusion was devoid of side-effects and produced some clinical benefits in the first 2 cases, concomitantly with an increased ex vivo anti-EBV CTL activity and a reduction in viral load.…”

confidence: 99%

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

Merlo¹,

Turrini²,

Dolcetti³

et al. 2010

Haematologica

View full text Add to dashboard Cite

The Epstein-Barr virus has evolved a plethora of strategies to evade immune system recognition and to establish latent infection in memory B cells, where the virus resides lifelong without any consequence in the majority of individuals. However, some imbalances in the equilibrium between the inherent virus transforming properties and the host immune system can lead to the development of different tumors, such as lymphoproliferative disorders, Hodgkin's lymphoma, Burkitt's lymphoma, and nasopharyngeal carcinoma. The expression of viral antigens in malignant cells makes them suitable targets for immunotherapeutic approaches, which are mainly based on the ex vivo expansion of EBV-specific T cells. Indeed, the infusion of virus-specific cytotoxic T lymphocytes has proved not only to be safe and effective, but also capable of restoring or inducing a protective anti-virus immunity, which is lacking, albeit to a different extent, in every EBV-driven malignancy. The purpose of this review is to summarize the results of adoptive immunotherapy approaches for EBV-related malignancies, with particular emphasis on the immunological and virological aspects linked to the clinical responses obtained. Data collected confirm the clinical relevance of the use of EBV-specific cytotoxic T lymphocytes in the field of adoptive immunotherapy and suggest the increasing importance of this approach also against other tumors, concurrent with the increasing knowledge of the intimate and continuous interplay between the virus and the host immune system. -related disorders. Haematologica 210;95(10):1769-1777. doi:10.3324/haematol.2010 Citation: Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, and Rosato A. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV ©2010 Ferrata Storti Foundation. This is an open-access paper.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

show abstract

Correction of DiGeorge Anomaly with EBV-Induced Lymphoma by Transplantation of Organ-Cultured Thymus and Epstein–Barr-Specific Cytotoxic T Lymphocytes

Cited by 20 publications

References 26 publications

Epstein-Barr virus–positive T-cell lymphoma cells having chromosome 22q11.2 deletion: an autopsy report of DiGeorge syndrome

Epstein-Barr virus–positive T-cell lymphoma cells having chromosome 22q11.2 deletion: an autopsy report of DiGeorge syndrome

Autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for the treatment of persistent active EBV infection

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

Contact Info

Product

Resources

About